SEP-227,162

From Self-sufficiency
Jump to: navigation, search
SEP-227,162
Identifiers
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

SEP-227,162 is an antidepressant being developed by Sepracor which is currently in clinical trials. It acts as a serotonin-norepinephrine reuptake inhibitor. As of 1st July 2009, the compound has not shown sufficient efficacy, and its future development is unknown.[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)


35px This drug article relating to the nervous system is a stub. You can help ssf by expanding it.
  1. ↑ "SEP-225289". Retrieved 7 February 2010. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=SEP-227,162&oldid=22742"